HESKA CORP.
HESKA CORP.
Open: -
Change: -
Volume: -
Low: -
High: -
High / Low range: -
Type: Stocks
Ticker: HSKA
ISIN:

Heska Corporation Third Quarter 2019 Financial Results and Earnings Call Scheduled for November 5, 2019

  • 42
Heska Corporation Third Quarter 2019 Financial Results and Earnings Call Scheduled for November 5, 2019

PR Newswire

LOVELAND, Colo., Oct. 15, 2019 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, plans to report its third quarter 2019 financial performance in a press release on Tuesday, November 5, 2019 before the market opens, and to host an earnings call to discuss the results at 9 a.m. MT / 11 a.m. ET on the same day.

Heska Corporation (PRNewsfoto/Heska Corporation)

To access the conference call:

From within the United States, please dial 1-866-548-4713
From outside of the United States, please dial 1-323-794-2093
Reference Conference ID: 3413443

The earnings call will be webcast live from the Company's website at https://ir.heska.com/.

A telephonic replay will be available beginning at 2 p.m. ET November 5 and will continue through 11:59 p.m. ET on Tuesday, November 19, 2019. The webcast will be archived on www.heska.com for 90 days.

To access the replay:

From within the United States, please dial 1-844-512-2921
From outside the United States, please dial 1-412-317-6671
Reference Replay Pin Number: 3413443

About Heska
Heska Corporation (NASDAQ: HSKA - News) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through two business segments; Core Companion Animal Health ("CCA") represents approximately 85% of revenues, and Other Vaccines and Pharmaceuticals ("OVP") segment represents approximately 15% of revenues as of June 30, 2019. CCA segment includes Point of Care Laboratory testing instruments and consumables, primarily under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP segment includes private label vaccine and pharmaceutical production under third party agreements and channels, primarily for herd animal health.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/heska-corporation-third-quarter-2019-financial-results-and-earnings-call-scheduled-for-november-5-2019-300938340.html

SOURCE Heska Corporation

PR Newswire
PR Newswire

PR Newswire's news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.